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1. Introduction {#ehf212478-sec-0004}
===============

Both in ischaemic and non‐ischaemic cardiomyopathy, the presence of significant mitral regurgitation (MR) is an important predictor for all‐cause mortality and heart failure (HF) hospitalizations independent of left ventricular ejection fraction (LVEF).[1](#ehf212478-bib-0001){ref-type="ref"} To date, the most effective therapies for secondary MR are aimed at the underlying LV dysfunction. Given the main pathophysiological mechanism, that is, LV and annular dilatation, these include optimal medical HF therapy and cardiac resynchronization therapy (CRT) when appropriate. In particular, beta‐blockers and angiotensin‐converting enzyme inhibitors (ACE‐Is) are recommended for all patients with LV dysfunction and secondary MR.[2](#ehf212478-bib-0002){ref-type="ref"} By reversing LV unloading and LV remodelling, optimal HF therapy may reduce MR. Surprisingly, however, few studies have examined the effect of beta‐blockers[3](#ehf212478-bib-0003){ref-type="ref"}, [4](#ehf212478-bib-0004){ref-type="ref"}, [5](#ehf212478-bib-0005){ref-type="ref"}, [6](#ehf212478-bib-0006){ref-type="ref"} or ACE‐Is[7](#ehf212478-bib-0007){ref-type="ref"} therapies on secondary MR. Secondary MR may also dramatically improve after optimization of fluid status by diuretics through lowering of the LV filling pressures.[8](#ehf212478-bib-0008){ref-type="ref"} More robust data are available on the LV remodelling and synchronizing effects of CRT on secondary MR.[9](#ehf212478-bib-0009){ref-type="ref"}, [10](#ehf212478-bib-0010){ref-type="ref"}, [11](#ehf212478-bib-0011){ref-type="ref"}, [12](#ehf212478-bib-0012){ref-type="ref"}, [13](#ehf212478-bib-0013){ref-type="ref"}, [14](#ehf212478-bib-0014){ref-type="ref"}

In this study, we report our results in patients with chronic HF and at least moderate MR referred to our tertiary HF outpatient clinic for a second opinion, specific referral for MR intervention, and/or heart transplantation. The aims of this study were to investigate (i) in how many real‐world referred patients HF therapy could be optimized, (ii) the effect of optimized treatment on MR severity, and (iii) whether a reduction in MR resulted in an improvement of symptoms.

2. Methods {#ehf212478-sec-0005}
==========

2.1. Study patient definition {#ehf212478-sec-0006}
-----------------------------

All patients included in the study fulfilled the following inclusion criteria: (i) referred by a cardiologist to our tertiary HF outpatient clinic between 2005 and 2015 for a second opinion with (ii) therapy‐resistant symptomatic chronic HF New York Heart Association (NYHA) class 2 to 4, (iii) LVEF \<40%, and (iv) at least moderate MR. In addition, all included patients were required to have a baseline transthoracic echocardiogram before change in HF treatment at our tertiary HF outpatient clinic and a follow‐up transthoracic echocardiogram between 6 and 18 months. Exclusion criteria were prior valvular surgery and concomitant congenital heart disease.

2.2. Clinical data {#ehf212478-sec-0007}
------------------

The following variables were noted: gender, age, heart rate, systolic blood pressure, aetiology of HF, prior HF hospitalization in the last 12 months, NYHA class, and renal dysfunction \[defined as estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m^2^\].

2.3. Transthoracic echocardiography {#ehf212478-sec-0008}
-----------------------------------

Echocardiography was performed with a Sonos or iE33 system (Philips, Best, The Netherlands), equipped with an S5‐1 transducer according to a standard HF protocol. The following variables were measured both at baseline and follow‐up according to standard guidelines[15](#ehf212478-bib-0015){ref-type="ref"}, [16](#ehf212478-bib-0016){ref-type="ref"}, [17](#ehf212478-bib-0017){ref-type="ref"}: LV end‐diastolic diameter and volumes, LV end‐systolic diameter and volumes (LVESV), LVEF, left atrial (LA) diameter and volume, transmitral E‐wave, transmitral deceleration time, diastolic early septal wall velocity as assessed with tissue Doppler imaging (e′), tricuspid valve regurgitation velocity, caval vein diameter, MR severity \[according to seven scales (from 0 to 6): none, trivial, mild, mild to moderate, moderate, moderate to severe, and severe\],[17](#ehf212478-bib-0017){ref-type="ref"} and MR jet morphology in the LA (central or eccentric). LV volumes and LVEF were measured with TomTec triplane analysis in Imaging Arena (TomTec Imaging systems, Imaging Arena, version 4.6, Unterschleissheim, Germany). All measurements were performed by blinded observers: MR by M. L. G., LV volumes and ejection fraction by E. S., and all others by L. d. G. d. L.

2.4. Definition of responders {#ehf212478-sec-0009}
-----------------------------

A patient was considered a volume responder when LVESV decreased ≥15%, an LVEF responder when LVEF increased by ≥5% points, a clinical responder when NYHA class improved at least one category, and an MR responder when MR severity improved at least one category to maximally moderate.

2.5. Medication and devices {#ehf212478-sec-0010}
---------------------------

In all patients, the following drugs (including dosage) were noted at baseline and at the time of follow‐up echocardiography: ACE‐I or angiotensin receptor blocker (ARB), beta‐blocker, loop diuretic, mineralocorticoid receptor antagonist (MRA), and digoxin. Optimal treatment dosages were defined according to the guideline.[2](#ehf212478-bib-0002){ref-type="ref"} Also, other interventions like thyroid hormone or Vitamin‐D supplementation were noted. Finally, it was noted whether the patient had an implantable cardioverter defibrillator (ICD) or had undergone (upgrade to) CRT.

2.6. Statistical analysis {#ehf212478-sec-0011}
-------------------------

Statistical analysis was performed using SPSS version 21.0.0.1 (SPSS, IBM, Armonk, NY). Categorical data are presented as numbers and percentages, whereas continuous data are summarized as mean ± standard deviation or median value with range. Comparisons of proportions were performed with a two‐sided *Z* test. *P*‐values \<0.05 were considered significant.

The agreement between MR response, EF response, and LVESV volume response to the NYHA response was assessed by calculating the kappa coefficient (a value of 0.21 to 0.40 indicating a fair agreement, a value of 0.41 to 0.80 indicating a moderate agreement, and a value of \>0.80 indicating an excellent agreement).

3. Results {#ehf212478-sec-0012}
==========

3.1. Baseline clinical and echocardiographic characteristics {#ehf212478-sec-0013}
------------------------------------------------------------

Forty‐seven patients (mean age 52 ± 13 years, 68% male patients) were included in the study, see *Figure* [1](#ehf212478-fig-0001){ref-type="fig"}. As seen in *Table* [1](#ehf212478-tbl-0001){ref-type="table"}, heart rate was 81 ± 19 b.p.m., and systolic blood pressure 102 ± 15 mmHg. HF aetiologies were ischaemic in 14 (30%) patients, 25 (53%) patients were hospitalized because of HF in the previous 12 months, and NYHA class was 2.9 ± 0.6 \[NYHA 2 in 11 (23%), NYHA 3 in 30 (64%), and NYHA 4 in 6 (13%)\]. Significant renal dysfunction was present in 12 (26%) patients. Mean volumes were 265 ± 103 mL for LV end‐diastolic volume and 205 ± 97 mL for LVESV, and LVEF was 25% ± 9%. Moderate, moderate‐to‐severe, and severe MR was present in 11 (23%), 15 (32%), and 21 (45%) patients. As seen in *Table* [2](#ehf212478-tbl-0002){ref-type="table"}, ACE‐I/ARBs were present in 45 (96%) patients, beta‐blockers in 37 (79%), diuretics in 42 (89%), MRAs in 32 (68%), and digoxin in 12 (26%). However, optimal doses of ACE‐I/ARBs were present in three (6%) patients, and optimal doses of beta‐blockers in four (9%). CRT was present in 10 (21%) patients (CRT‐D in nine and CRT‐P in one), and an isolated ICD was present in 13 (28%) patients.

![Inclusion patients. HF, heart failure; LVAD, left ventricular assist device; MR, mitral regurgitation; MVP, mitral valve plasty.](EHF2-6-936-g001){#ehf212478-fig-0001}

###### 

Clinical and echocardiographic data

                                                                    All patients baseline N = 47              All patients follow‐up N = 47                                MR responder N = 27                                  MR non‐responder N = 20
  ---------------------------------------------------------------- ------------------------------ ------------------------------------------------------ ------------------------------------------------------- -----------------------------------------------------
  Clinical data                                                                                                                                                                                                  
  Male gender                                                                 32 (68%)                                                                                          17 (63%)                                               15 (75%)
  Age (years)                                                                 52 ± 13                                                                                            56 ± 12                                                49 ± 13
  Heart rate (bpm)                                                            81 ± 19                                    66 ± 12                                                 85 ± 20                                                77 ± 16
  Systolic blood pressure                                                     102 ± 15                                                                                          101 ± 13                                               103 ± 18
  Ischaemic aetiology                                                         14 (30%)                                                                                           8 (30%)                                                6 (30%)
  Prior HF hospitalization                                                    25 (53%)                                                                                          15 (56%)                                               10 (50%)
  NYHA class III or IV                                                        36 (77%)                                   12 (26%)                                               21 (78%)                                               15 (75%)
  Glomerular filtration rate                                                  61 ± 20                                    58 ± 21                                                 64 ± 22                                                56 ± 14
  Renal dysfunction[a](#ehf212478-note-0002){ref-type="fn"}                   12 (26%)                                   10 (21%)                                                7 (26%)                                                5 (25%)
  Echocardiographic data[b](#ehf212478-note-0003){ref-type="fn"}                                                                                                                                                 
  LVEDD                                                                     68.4 ± 13.2                                66.8 ± 11.9                                             68.3 ± 12.8                                            68.4 ± 13.8
  LVEDD delta                                                                                                          −1.6 ± 11.2                                             −4.8 ± 13.5                                             1.1 ± 8.2
  LVESD                                                                     61.3 ± 13.8                                56.4 ± 13.1                                             60.8 ± 13.4                                            61.6 ± 14.5
  LVESD delta                                                                                      −4.9 ± 11.1[\*](#ehf212478-note-0020){ref-type="fn"}   −8.0 ± 13.4[\*](#ehf212478-note-0020){ref-type="fn"}                        −2.3 ± 8.1
  LVEDV                                                                    264.6 ± 102.6                              246.5 ± 100.3                                           272.7 ± 119.6                                          257.8 ± 88.6
  LVEDV delta                                                                                                          −18.1 ± 86.6                                           −48.0 ± 112.6                                           6.9 ± 46.1
  LVESV                                                                     204.8 ± 97.0                               179.5 ± 99.1                                           210.4 ± 113.5                                          200.0 ± 83.6
  LVESV delta                                                                                                          −25.3 ± 89.9                                           −54.2 ± 120.5                                           −0.9 ± 42.7
  LVEF                                                                       24.5 ± 9.3                                30.7 ± 11.7                                             25.3 ± 9.4                                             24.0 ± 9.4
  LVEF delta                                                                                       6.1 ± 12.2[\#](#ehf212478-note-0021){ref-type="fn"}     9.0 ± 16.2[\*](#ehf212478-note-0020){ref-type="fn"}    3.7 ± 7.0[\*](#ehf212478-note-0020){ref-type="fn"}
  LA diameter                                                                49.5 ± 7.8                                 46.4 ± 9.0                                             47.9 ± 7.1                                             50.9 ± 8.3
  LA diameter delta                                                                                −3.1 ± 8.1[\#](#ehf212478-note-0021){ref-type="fn"}     −6.7 ± 8.3[\#](#ehf212478-note-0021){ref-type="fn"}                        −0.1 ± 6.8
  LA volume                                                                 117.1 ± 37.7                               102.6 ± 49.6                                           115.1 ± 36.0                                           118.8 ± 39.9
  LA volume delta                                                                                                      −14.5 ± 52.1                       −41.8 ± 37.4[\#](#ehf212478-note-0021){ref-type="fn"}                       8.5 ± 52.4
  e′                                                                         4.7 ± 1.7                                  5.2 ± 2.0                                               4.4 ± 1.8                                              4.9 ± 1.7
  e′ delta                                                                                                              0.5 ± 1.9                                               0.5 ± 1.9                                              0.5 ± 1.9
  E/e′                                                                       22.5 ± 9.1                                17.6 ± 12.1                                             24.0 ± 10.6                                            21.2 ± 7.7
  E/e′ delta                                                                                       −4.9 ± 13.2[\*](#ehf212478-note-0020){ref-type="fn"}   −8.6 ± 13.9[\*](#ehf212478-note-0020){ref-type="fn"}                        −1.8 ± 12.2
  TR velocity                                                                2.9 ± 0.6                                  2.6 ± 0.8                                               2.9 ± 0.6                                              3.0 ± 0.6
  TR velocity delta                                                                                −0.3 ± 0.8[\*](#ehf212478-note-0020){ref-type="fn"}     −0.6 ± 0.7[\#](#ehf212478-note-0021){ref-type="fn"}                        −0.1 ± 0.7
  IVC diameter                                                               20.9 ± 5.2                                 16.3 ± 4.9                                             20.1 ± 5.5                                             21.5 ± 5.0
  IVC diameter delta                                                                               −4.6 ± 5.6[\#](#ehf212478-note-0021){ref-type="fn"}     −5.3 ± 6.1[\#](#ehf212478-note-0021){ref-type="fn"}    −3.9 ± 5.2[\#](#ehf212478-note-0021){ref-type="fn"}
  MR central jet                                                              26 (55%)                                   26 (55%)                                               16 (59%)                                               10 (50%)
  MR severe                                                                   21 (45%)                                   6 (13%)                                                13 (48%)                                                8 (40%)

HF, heart failure; IVC, inferior vena cava; LA, left atrium; LVEDD, left ventricular end‐diastolic diameter; LVEDV, LV end‐diastolic volume; LVEF, LV ejection fraction; LVESD, LV end‐systolic diameter; LVESV, LV end‐systolic volume; MR, mitral regurgitation; NYHA, New York Heart Association; TR, tricuspid regurgitation.

Glomerular filtration rate \<45 mL/min/1.73 m^2^.

In the MR responder columns, only baseline and delta values are displayed. Limited to the 35 patients with complete echo data available.

*P* \< 0.05.

*P* \< 0.01.

###### 

Baseline heart failure therapy and changes in the study population (n = 47)

                        Baseline   Follow‐up                                                                            
  --------------------- ---------- ----------- ---------- ------------------------------------------------- ----------- ---------------------------------------------------
  ACE‐inhibitors/ARBs   45 (96%)   3 (6%)      22 (47%)   2 (4%)                                            47 (100%)   18 (38%)[\*](#ehf212478-note-0006){ref-type="fn"}
  Beta‐blocker          37 (79%)   4 (9%)      20 (43%)   9 (19%)                                           46 (98%)    14 (30%)[\*](#ehf212478-note-0006){ref-type="fn"}
  Diuretics             42 (89%)               22 (47%)   3 (6%)                                            45 (96%)    
  MRAs                  32 (68%)               3 (6%)     7 (15%)                                           39 (83%)    
  Digoxin               12 (26%)               0 (0%)     25 (53%)                                          37 (76%)    
  CRT‐P                 1 (2%)                            0 (0%)                                            1 (2%)      
  CRT‐D                 9 (19%)                           8 (17%)[a](#ehf212478-note-0005){ref-type="fn"}   17 (36%)    
  ICD only              13 (28%)                          5 (11%)                                           15 (32%)    

ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CRT‐D, cardiac resynchronization therapy defibrillator; CRT‐P, cardiac resynchronization therapy pacemaker; ICD, implantable cardioverter defibrillator; MRAs, mineralocorticoid receptor antagonists.

Including three upgrades from ICD only.

*P* \< 0.001 compared with baseline.

3.2. Medical interventions {#ehf212478-sec-0014}
--------------------------

Ten patients (21%) were immediately after first outpatient assessment hospitalized to optimize HF. As seen in *Table* [2](#ehf212478-tbl-0002){ref-type="table"} and *Figure* [2](#ehf212478-fig-0002){ref-type="fig"}, in the total group of patients, ACE‐I/ARBs were initiated in two (4%) patients and up‐titrated in 22 (47%) patients, beta‐blockers were initiated in nine (19%) patients and up‐titrated in 20 (43%) patients, diuretics were initiated in three (6%) patients and up‐titrated in 22 (47%) patients, MRAs were initiated in seven (15%) patients and up‐titrated in three (6%) patients, and digoxin was initiated in 25 (52%) patients and up‐titrated in none. At follow‐up, optimal doses of ACE‐I/ARBs were present in 18 (38%) patients compared with three (6%) at baseline (*P* \< 0.001), and optimal doses of beta‐blockers were present in 14 (30%) patients compared with four (9%) at baseline (*P* \< 0.001). Six (13%) patients were on the evidence‐based dose of both beta‐blockers and ACE‐inhibitors/ARBs at the time of follow‐up echocardiography vs. 0 (0%) at baseline. Heart rate decreased from 81 ± 19 to 66 ± 12 b.p.m. (*P* \< 0.001).

![Baseline (left) and change (right) in heart failure therapy. ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CRT‐D, cardiac resynchronization therapy defibrillator; MRA, mineralocorticoid receptor antagonist.](EHF2-6-936-g002){#ehf212478-fig-0002}

3.3. Device interventions {#ehf212478-sec-0015}
-------------------------

As seen in *Table* [2](#ehf212478-tbl-0002){ref-type="table"}, CRT was initiated in eight (17%) patients, of whom in three patients, existing ICD therapy was upgraded to a CRT‐D system. An additional five patients received an isolated ICD.

3.4. Clinical and echocardiographic improvement {#ehf212478-sec-0016}
-----------------------------------------------

After a mean of 14 ± 4 months, NYHA class improved from 2.9 ± 0.6 to 2.0 ± 0.9 (*P* \< 0.001), and 32 patients (68%) were clinical responders. MR class improved from 5.2 ± 0.8 to 3.6 ± 1.5 (*P* \< 0.001), and 27 patients (57%) were MR responders (*Figure* [3](#ehf212478-fig-0003){ref-type="fig"}). In these latter patients, vena contracta width improved from 7.0 ± 1.4 to 2.7 ± 1.2 mm (*P* \< 0.001), whereas in the non‐responders, no significant improvement was seen in vena contracta width (7.3 ± 1.5 vs. 6.9 ± 1.6 mm, *P* = not significant).

![New York Heart Association (NYHA) class (left) and mitral regurgitation (MR) (right) response to optimize treatment. Thickness of the line corresponds to the number of patients.](EHF2-6-936-g003){#ehf212478-fig-0003}

Left ventricular end‐systolic volume non‐significantly improved from 205 ± 97 to 180 ± 99 mL (*P* = not significant), and 12 patients (34%) were volumetric responders. LVEF improved from 24% ± 9% to 31% ± 12% (*P* \< 0.01), and 17 patients (49%) were LVEF responders.

3.5. Predictors for mitral regurgitation improvement {#ehf212478-sec-0017}
----------------------------------------------------

As seen in *Table* [1](#ehf212478-tbl-0001){ref-type="table"}, none of the baseline variables predicted improvement (responders) in MR. Associated with MR improvement were a decrease in LV end‐systolic diameter, LA diameter and volume, E/e′, tricuspid regurgitation velocity and inferior vena cava dimension, and an increase in LVEF.

3.6. Relation between mitral regurgitation and ejection fraction improvement vs. New York Heart Association response {#ehf212478-sec-0018}
--------------------------------------------------------------------------------------------------------------------

The positive predictive value of MR response to NYHA response was 88%; the negative predictive value was 53%, agreement 69%, and kappa 0.39. The positive predictive value of LVEF response to NYHA response was 76%; the negative predictive value was 44%, agreement 60%, and kappa 0.21. The positive predictive value of LVESV volume response to NYHA response was 75%; the negative predictive value was 39%, agreement 51%, and kappa 0.12.

3.7. Relation between mitral regurgitation improvement and renal dysfunction {#ehf212478-sec-0019}
----------------------------------------------------------------------------

Estimated glomerular filtration rate non‐significantly decreased from 61 ± 20 to 58 ± 21 mL/min/1.73 m^2^. In MR responders, eGFR remained stable (0 ± 13), whereas in MR non‐responders, eGFR deteriorated with 8 ± 12 mL/min/1.73 m^2^ (*P* \< 0.05). In both EF responders and non‐responders, eGFR remained stable.

4. Discussion {#ehf212478-sec-0020}
=============

The main findings of this study in patients referred by cardiologists to our tertiary HF clinic with therapy‐resistant HF and at least moderate MR are (i) although the vast majority of the referred patients received recommended medication, optimal dosages were seen in only a very small minority, (ii) initiation of therapy resulted in the presence of the recommended medication in virtually all patients, (iii) despite up‐titration of recommended medication in almost half of the patients, still approximately only one‐third of patients could tolerate the maximum recommended drug dosages, (iv) MR reduced significantly in over half of the patients, and (v) MR reduction best correlated to NYHA improvement.

4.1. Medical therapy {#ehf212478-sec-0021}
--------------------

Medical therapy for HF consists of vasodilators (ACE‐Is), beta‐blockers, MRAs, and diuretics. The main effects of these drugs include reversal or delay of LV remodelling and reduction of MR through lowering filling pressures. The use of afterload‐reducing agents, including ACE‐Is, might reduce MR volume and improve LV forward stroke volume by decreasing the pressure gradient between the LV and the left atrium through systolic unloading. A similar effect of reduction in MR is obtained with preload reduction through the use of diuretics that decrease LV size and tethering with a consequent decrease in MR volume.[8](#ehf212478-bib-0008){ref-type="ref"} It is well known that ACE‐Is and beta‐blockers reduce mortality and morbidity in symptomatic patients with HF with reduced LVEF[18](#ehf212478-bib-0018){ref-type="ref"}, [19](#ehf212478-bib-0019){ref-type="ref"}, [20](#ehf212478-bib-0020){ref-type="ref"} and are complementary. According to the guideline, these drugs should be gradually up‐titrated to the maximum tolerated dose.[2](#ehf212478-bib-0002){ref-type="ref"} In this study, it is shown that although referred patients often were on ACE‐Is and beta‐blockers, optimal doses were rarely seen. In a significant number of patients, beta‐blockers could be initialized by the HF specialist, and drugs could be up‐titrated. Still, at the last moment of assessment (between 6 and 18 months), optimal doses of ACE‐Is and beta‐blockers were only seen in one‐third of our patients. Hypotension, bradycardia, and renal failure are well‐known causes of failure to up‐titrate HF drugs, in particular in patients with advanced HF. Patients referred to our outpatient HF clinic represent the sickest of the sick: the majority were hospitalized because of HF in the previous 12 months, and outpatient NYHA class was in the vast majority NYHA class 3 or 4. Further evidence for the severity of HF disease is seen in the haemodynamic characteristics. The mean heart rate of 81 is quite comparable with patients included in the major HF landmark trials,[18](#ehf212478-bib-0018){ref-type="ref"}, [19](#ehf212478-bib-0019){ref-type="ref"}, [20](#ehf212478-bib-0020){ref-type="ref"} but the systolic blood pressure of 102 mmHg is significantly lower than the 120--130 mmHg range reported in the major HF landmark trials[18](#ehf212478-bib-0018){ref-type="ref"}, [19](#ehf212478-bib-0019){ref-type="ref"}, [20](#ehf212478-bib-0020){ref-type="ref"} that included also mainly patients in NYHA class 3 or 4.

Despite these issues, the subscription of ACE‐Is and beta‐blockers in 100% and 98% of patients is a remarkable achievement. For example, in a Spanish prospective cohort of patients hospitalized for HF from 2008 to 2011, beta‐blockers were after 12 months only present in 68% of patients,[21](#ehf212478-bib-0021){ref-type="ref"} and numbers also seen in other registries like the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE‐HF) registry.[22](#ehf212478-bib-0022){ref-type="ref"} In this latter trial, target doses of metoprolol and carvedilol were seen in only 8% and 18% of patients 3 months after discharge.

In the recently published European Society of Cardiology Heart Failure Long‐Term Registry, patients with chronic HF had 1 year follow‐up ACE‐Is/ARBs, beta‐blockers, and MRAs in 87%, 89%, and 59% of patients, respectively.[23](#ehf212478-bib-0023){ref-type="ref"} In these trials, baseline values of systolic blood pressure and heart rate were 124 ± 21 mmHg and 73 ± 15 b.p.m., and 25% of patients were in NYHA class III or IV. So our patients referred because of refractory HF were also compared with this contemporary registry clearly the sickest of the sick.

4.2. Device therapy {#ehf212478-sec-0022}
-------------------

According to the baseline LVEF, 63% of patients who had a primary prophylactic ICD indication had an ICD (with or without CRT) implanted before referral. At the end of the follow‐up period, this percentage was 94%; in addition, all patients with left bundle branch block had CRT. These numbers seem also much better than the low numbers reported in the European Society of Cardiology Heart Failure Long‐Term Registry, although it cannot be clearly distillated from this registry how many patients actually had a clear indication for CRT and/or ICD.[23](#ehf212478-bib-0023){ref-type="ref"}

4.3. Mitral regurgitation {#ehf212478-sec-0023}
-------------------------

In HF patients, the presence of significant MR is a significant predictor for mortality[1](#ehf212478-bib-0001){ref-type="ref"}, [24](#ehf212478-bib-0024){ref-type="ref"}, [25](#ehf212478-bib-0025){ref-type="ref"} and exercise capacity.[26](#ehf212478-bib-0026){ref-type="ref"} By inclusion, all our patients had at least moderate MR. The described therapeutic interventions resulted in a significant reduction of MR in over half of the patients, consistent with findings recently published by Stolfo *et al*.[27](#ehf212478-bib-0027){ref-type="ref"} The relation between clinical effects and MR reduction by medical therapy is not well described in the literature. In contrast, it is well known that improvement of significant MR by CRT is sustained and patients with less residual MR 6 months after CRT have a better survival.[28](#ehf212478-bib-0028){ref-type="ref"} In this study, it is clearly shown that MR reduction is best related to NYHA class improvement. The potential improvement in MR by HF therapy optimization by a dedicated HF cardiologist may prevent in a large number of HF patients the need for surgical or percutaneous mitral valve interventions.

4.4. Limitations {#ehf212478-sec-0024}
----------------

The major limitations of this study are the retrospective character and the limited number of patients. The latter was mainly caused by our stringent study inclusion criteria, excluding patients in whom adjustment of therapy was started before the first echo in our centre. Also, approximately 20% of patients were deemed to have irreversible HF and referred for heart transplantation. Considering the total cohort of patients, a significant MR reduction in over half of the patients may therefore be an overestimation. On the other hand, approximately 10% of patients was referred back with medical advices thought to be easily implemented by the referring physician, and it may be expected that in these patients, even a larger proportion of patients would have shown improvement in MR. Finally, sacubitril/valsartan was not available at the time of our study. Sacubitril/valsartan has been not only shown to reduce the rate of HF hospitalization and cardiovascular mortality in selected symptomatic patients with HF with an LVEF \<35%[29](#ehf212478-bib-0029){ref-type="ref"} but also to reduce MR severity in patients initially on optimal medical therapy with an ACE‐I/ARB and beta‐blocker and significant secondary MR.[30](#ehf212478-bib-0030){ref-type="ref"}

5. Conclusions {#ehf212478-sec-0025}
==============

Initiation and up‐titration of recommended HF therapy in patients referred to our tertiary HF outpatient clinic resulted in significant MR reduction in over half of the patients, emphasizing the importance of optimal medical treatment in these very sick cardiac patients with otherwise grave prognosis. MR reduction was best correlated to NYHA improvement.
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